Figure 1.
Complement pathway inhibition. Sutimlimab inhibits the pathway at C1s and can inhibit both the classical and alternate complement pathways, unlike eculizumab. Reproduced from Berentsen et al. (2022).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.